A Prospective, Observational Study to Assess the Long-Term Safety of Ixekizumab Compared with Other Therapies Used in the Treatment of Adults with Moderate-to-Severe Psoriasis in the Course of Routine Clinical Care (I1F-MC-RHBT)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/32737
• EU PAS number:
  EUPAS18132
• Study ID:
  32737
• Official title and acronym:
  A Prospective, Observational Study to Assess the Long-Term Safety of Ixekizumab Compared with Other Therapies Used in the Treatment of Adults with Moderate-to-Severe Psoriasis in the Course of Routine Clinical Care (I1F-MC-RHBT)
• DARWIN EU® study:
  No
• Study countries:
  Canada

  United States
• Study status:
  Ongoing

Research institutions and networks

Institutions

Corrona Rheumatoid Arthritis Registry

Study timelines

Date when funding contract was signed

Actual: 15/07/2015

Study start date

Actual: 20/04/2016

Date of final study report

Planned: 31/05/2030

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company

Study protocol

Initial protocol

RHBT 05 Protocol(b)_Redacted

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)